Loading...

RxSight, Inc.

RXSTNASDAQ
Healthcare
Medical - Devices
$8.92
$0.19(2.18%)

RxSight, Inc. (RXST) Financial Performance & Income Statement Overview

Review RxSight, Inc. (RXST) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.

Revenue Growth
57.09%
57.09%
Operating Income Growth
26.41%
26.41%
Net Income Growth
43.52%
43.52%
Operating Cash Flow Growth
59.26%
59.26%
Operating Margin
-27.06%
27.06%
Gross Margin
68.42%
68.42%
Net Profit Margin
-20.52%
20.52%
ROE
-11.56%
11.56%
ROIC
-14.74%
14.74%

RxSight, Inc. (RXST) Income Statement & Financial Overview

Review RxSight, Inc. RXST income statement with detailed quarterly and annual figures.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$37.90M$40.21M$45.41M$34.89M
Cost of Revenue$9.57M$11.43M$20.19M$10.64M
Gross Profit$28.33M$28.79M$25.22M$24.25M
Gross Profit Ratio$0.75$0.72$0.56$0.70
R&D Expenses$10.37M$9.21M$8.84M$8.29M
SG&A Expenses$28.64M$28.21M$25.61M$24.29M
Operating Expenses$39.003M$37.42M$34.45M$32.58M
Total Costs & Expenses$48.57M$48.84M$54.63M$43.22M
Interest Income$0.00$2.71M$2.91M$2.28M
Interest Expense-$6000.00$5000.00$5000.00$6000.00
Depreciation & Amortization$0.00$523000.00$1.14M$820000.00
EBITDA-$10.67M-$5.40M-$5.18M-$5.24M
EBITDA Ratio-$0.28-$0.13-$0.11-$0.15
Operating Income-$10.67M-$8.63M-$9.23M-$8.33M
Operating Income Ratio-$0.28-$0.21-$0.20-$0.24
Other Income/Expenses (Net)$2.50M$2.70M$2.90M$2.27M
Income Before Tax-$8.17M-$5.93M-$6.33M-$6.06M
Income Before Tax Ratio-$0.22-$0.15-$0.14-$0.17
Income Tax Expense$18000.00$12000.00$13000.00$16000.00
Net Income-$8.19M-$5.94M-$6.34M-$6.08M
Net Income Ratio-$0.22-$0.15-$0.14-$0.17
EPS-$0.20-$0.15-$0.16-$0.16
Diluted EPS-$0.20-$0.15-$0.16-$0.16
Weighted Avg Shares Outstanding$40.51M$40.36M$39.79M$38.46M
Weighted Avg Shares Outstanding (Diluted)$40.51M$40.36M$39.79M$38.46M

Over the past four quarters, RxSight, Inc. demonstrated steady revenue growth, increasing from $34.89M in Q2 2024 to $37.90M in Q1 2025. Operating income reached -$10.67M in Q1 2025, maintaining a consistent -28% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$10.67M, reflecting operational efficiency. Net income dropped to -$8.19M, with EPS at -$0.20. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;